7/102 sources · 2 publishersUpdated Oct 14, 12:22 UTC
Profound Medical presents TULSA data showing functional benefits and lower‑field MRI feasibility
Profound Medical disclosed results from five abstracts at the 15th Interventional MRI Symposium. The data include real‑world outcomes from Mayo Clinic registries, a randomized CAPTAIN trial that showed superior erectile‑function and continence preservation versus robotic prostatectomy, and a technical validation of the TULSA‑PRO system on a 0.55 T MRI scanner. The company said the findings support broader clinical adoption of the TULSA Procedure.
Why it matters
Profound Medical said the evidence could expand the procedure’s use and reduce equipment barriers, which may increase future sales of its TULSA‑PRO system.
Key facts
- 1The CARE Registry analysis covered 197 patients with a median follow‑up of 24 months. stocktitan.net
- 2Median PSA nadir was 0.23 ng/mL after whole‑gland treatment, 0.60 ng/mL after subtotal, and 1.10 ng/mL after focal treatment. stocktitan.net
- 3Catheterization duration decreased from a median of 13.5 days after whole‑gland treatment to seven days after subtotal or focal treatment. stocktitan.net
- 4In the CAPTAIN trial, whole‑gland TULSA patients were more than twice as likely to preserve erectile function and pad‑free continence (risk ratio 2.1, p=0.004). stocktitan.net
- 5Mayo Clinic Florida reported outcomes for 58 patients with up to 4.5 years of follow‑up. stocktitan.net
- 6Mayo Clinic Rochester’s prospective study evaluated 41 patients, with mean PSA falling from 7.7 ng/mL to approximately 2.3–2.6 ng/mL. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.